Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Sebi may widen 50% overlap rule to thematic passive mutual fund schemes
Curb on number of smart-beta schemes also likely; move aimed at curbing proliferation in segment

Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.

Small-caps, PSUs and pharma remain Gautam Shah's top market themes for 2026
Gautam Shah, Founder of Goldilocks Global Research, sees the Nifty remaining range-bound between 23,150 and 24,000, while forecasting the small-cap index could rise to 20,000. Shah also believes Indian IT stocks are nearing a bottom and that PSU stocks could deliver 25-30% returns over the next 12-18 months.
Alkem Labs shares in focus as Goldman, Morgan Stanley, others purchase stake in Rs 930-crore block deal
Shares of Alkem Laboratories will be in focus after block deals worth around Rs 930 crore saw 17.88 lakh shares traded at Rs 5,200 apiece on Tuesday. Promoter-linked entities offloaded their stake, while domestic mutual funds and foreign institutional investors emerged as key buyers, signalling strong institutional participation. The company also launched semaglutide pre-filled syringes in India.

Leapfrog, IFC and NIIF eye ₹400 crore minority stake in Marengo Asia Healthcare
Marengo will likely use the proceeds to fund its next level growth phase, including inorganic growth plans and expanding its Gurgaon and Faridabad capacity
Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?
Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pharma index rebounded from early losses to rise nearly 1%, crossing the 25,000 mark and hitting a fresh 52-week high of 25,043.
Nifty May futures trade at a premium
Dixon Technologies (India), Cipla and HDFC Bank were the top traded contracts.
Unique Picks: 6 stocks held by only one MF scheme in April, falling up to 40% in CY26
An analysis of mutual fund portfolios revealed 29 stocks held exclusively by single schemes, with most underperforming in CY26. However, Satin Creditcare Network, Rossell Techsys, and Amanta Healthcare bucked the trend, delivering strong returns. Brooks Laboratories and EFC (I) were among those experiencing significant declines.
Sensex slumps 847 pts; Nifty trades below 23,950 mark; VIX rallies 8.40%
The Nifty slipped below the 23,950 mark. Pharma, IT and FNCG shares advanced while all the sectoral indices on the NSE traded in the red.

Nippon India Mutual Fund raises stake in this healthcare stock. Do you own? - Mint
Nippon India Mutual Fund raises stake in this healthcare stock. Do you own?Mint
Where to invest now: SBI MF prefers large caps, pharma, PSU banks
Ruchit Mehta, Head of Research at SBI Mutual Fund, prefers CDMO and hospital plays within pharma, citing stronger growth prospects over generics. He sees large caps as attractive on valuations, while midcaps require selectivity amid earnings risks. PSU banks may outperform in the near term due to stronger loan growth, but asset quality risks could emerge over the next 2–3 quarters if global disruptions persist.